Why Pfizer Will Make More Money Than Originally Expected in 2021

We've all known for quite a while that Pfizer (NYSE: PFE) was likely to make billions of dollars from its COVID-19 vaccine. Granted, the big drugmaker has to share any revenue generated with its partner, BioNTech (NASDAQ: BNTX). But a lot of money is about to begin flowing into Pfizer's coffers thanks to Comirnaty, the brand name the company bestowed on COVID-19 vaccine BNT162b2.

Whatever amount you might have expected from Comirnaty, you might want to add to it. Here's why Pfizer will make more money than originally expected in 2021 from its coronavirus vaccine.

Image source: Getty Images.

Continue reading

Source Fool.com